HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY

Autres langues Horizon Therapeutics Public Limited Company

Actions

HZNP

IE00BQPVQZ61

Temps Différé Nasdaq Autres places de cotation 22:00:00 29/09/2023			Varia. 5j.	Varia. 1 janv.
115.69 ^USD	-.--%		+0.07%	+1.66%

29/09	Horizon Therapeutics Public Limited Company annonce une nouvelle analyse du respect d'un traitement complet et ininterrompu par Tepezza pour améliorer les résultats des patients atteints d'une maladie oculaire thyroïdienne.	CI
14/09	Nvidia et Amgen soutiennent la levée de fonds de 273 millions de dollars de Generate:Biomedicines, une société de développement de médicaments basés sur l'IA	ZR

Autres langues

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)	29/09
Horizon Therapeutics Public Limited Company Announces New Analysis of Adhering to Uninterrupted Full Course of Treatment with Tepezza to Support Thyroid Eye Disease Patient Outcomes	29/09
New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes	29/09
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)	27/09
Horizon Therapeutics plc Named to U.S. News & World Report's 2024 List of Best Companies to Work For in the Health Care Industry	27/09
Horizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care Industry	26/09
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)	25/09
EMEA Morning Briefing : Shares Seen Lower at Start of the Week	25/09
Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 List	19/09
Nvidia, Amgen back AI-driven drug firm Generate:Biomedicines' $273 mln fundraise	14/09
Horizon Therapeutics, Q32 Bio Say First Patient Dosed in Phase 2 Trial of Bempikibart in Severe Alopecia Areata	13/09
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart for Severe Alopecia Areata	13/09
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata	13/09
FTC, States Agree On Path Forward For Amgen's Horizon Therapeutics Deal	11/09
Horizon Therapeutics plc, Rule 2.12 Announcement	07/09
Horizon Therapeutics plc (“Horizon”) Rule 2.12 Announcement	06/09
The FTC "Settles" For A Conduct Consent Decree To Resolve Its Challenge To The Amgen-Horizon Merger	06/09
Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement	05/09
FTC settlement could shelter Amgen from US price cuts, taxes	05/09
Global markets live: Arm, Amgen, Lloyds, Novo Nordisk, Nestlé...	04/09

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse

Autres langues Horizon Therapeutics Public Limited Company

Actions

HZNP

IE00BQPVQZ61

Autres langues

Filtres